Clinical Trial Protocol
Iranian Registry of Clinical Trials

22 Jul 2026

Randomized, single-dose, crossover comparative bioequivalence study of the Celecoxib 200 mg capsules produced by Daana pharmaceutical Co versus Celebrex® (Pfizer company) in 24 healthy males under fasting conditions

Protocol summary

Study aim
To demonstrate bioequivalence of single dose test formulation of Dana Celecoxib 200 mg capsules versus Celebrex®(Pfizer Co.)

Design
Single dose, randomized and crossover bioequivalence study of Celecoxib 200 mg capsules by Dana Co. with Celebrex® (Pfizer Co.) in 24 healthy male in two groups under fasting condition.

Settings and conduct
Study place: Drug Applied Research Center affiliated to Tabriz University of Medical Science. Place for Blood and plasma sample analysis: Imam Reza Medical Research and Trainning Hospital. 24 healthy male volunteers received each of two test or reference Celecoxib 200 mg tablets in random sequence according to the randomization schedule. The interval between receiving the medicine (washout period) is 7 days, If the first sequence receives Iranian medicine, they will receive brand medicine. Blood samples will be taken from all participants before receiving the drug and 48 hours after that at determined time points: 0.5، 1، 1.5، 2، 2.5، 3، 3.5، 4، 6، 8، 12، 24 and 48 hours.

Participants/Inclusion and exclusion criteria
Healthy male subjects in the age range of 18-60 years and BMI (Body Mass Index) of 18.5-30. Exclusion criteria: Subjects with BP ≤ 90/60 mm/Hg or BP ≥ 140/90 mm/Hg Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function or a history of TB, epilepsy, asthma, DM, psychosis or glaucoma and regular smoker.

Intervention groups
Intervention group (Test): Celecoxib 200 mg capsules by Dana Co. is the test product. In each period, 12 of 24 subjects will be given single oral dose of this product. Control group (Reference): Celebrex® (Pfizer Co.) is the reference product. In each period, 12 of 24 subjects will be given single dose of this product.

Main outcome variables
Peak Plasma Concentration (Cmax); Area under the concentration-time curve (AUC).

General information

Reason for update

Acronym

IRCT registration information
IRCT registration number: **IRCT20200407046981N11**
Registration date: **2021-06-23, 1400/04/02**
Registration timing: **prospective**

Last update: **2021-06-23, 1400/04/02**
Update count: **0**

Registration date
2021-06-23, 1400/04/02

Registrant information

Name
Fatima Molavi

Name of organization / entity

Country
Iran (Islamic Republic of)

Phone
+98 41 3336 2700

Email address
molavif@tbzmed.ac.ir

Recruitment status
Recruitment complete

Funding source

Expected recruitment start date
2021-07-21, 1400/04/30

Expected recruitment end date
2021-09-21, 1400/06/30
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty

Scientific title
Randomized, single-dose, crossover comparative bioequivalence study of the Celecoxib 200 mg capsules produced by Daana pharmaceutical Co versus Celebrex® (Pfizer company) in 24 healthy males under fasting conditions

Public title
Study of absorption and elimination rate of Celecoxib 200 mg capsules in comparison with standard capsules of Celecoxib (Celebrex®).
Purpose
Health service research
Inclusion/Exclusion criteria
Inclusion criteria:
The weight limit for each volunteer is between 60 and 100 kg. All volunteers must be non-smokers. They must be healthy in terms of liver, kidney, respiratory system, mental and other general health characteristics that will be assessed.
Exclusion criteria:
Known hypersensitivity or idiosyncratic reaction to Celecoxib or any ingredients. Subjects with BP ≤ 90/60 mm/Hg or BP ≥ 140/90 mm/Hg. Regular smoker who smokes more than ten cigarettes daily. Taking any medicine during two week before dosing.
Age
From **18 years** old to **60 years** old
Gender
Male

Phase
Bioequivalence
Groups that have been masked
No information
Sample size
Target sample size: **24**
More than 1 sample in each individual
Number of samples in each individual: **28**
In each period, 14 blood samples are collected from each subject and this study includes 2 periods.
Randomization (investigator's opinion)
Randomized
Randomization description
First, a table of random numbers from 1 to 24 is created. The table numbers are assigned to individuals in the order in which the candidates enter the list on the day of the experiment, and the candidates in two groups with numbers 1-12 and numbers 13-24 will receive reference and test medicine, respectively.
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Crossover
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Tabriz University of Medical Science
Street address
Third floor, central building No. 2, Golgasht street, Tabriz University of Medical Science, Tabriz, Iran
City
Tabriz
Province
East Azarbaijan
Postal code
5166614766
Approval date
2021-05-31, 1400/03/10
Ethics committee reference number
IR.TBZMED.REC.1400.252

Health conditions studied

1

Description of health condition studied
analgesic and anti inflammation
ICD-10 code
ICD-10 code description

Primary outcomes

1

Description
Peak Plasma Concentration (Cmax)
Timepoint
At 0 (before dosing), 0.5، 1، 1.5 ،2، 2.5، 3، 3.5، 4، 6، 8 ، 12، 24 and 48 hour after dosing
Method of measurement
High-performance liquid chromatography—mass spectrometry (HPLC-MS)

Secondary outcomes

1

Description
AUC (Area Under the Concentration-Time Curve)
Timepoint
During 2 months after intervention

Method of measurement
Using non-compartmental model of Win-Nonlin Professional software version 3.2.A (Pharsight Corporation, USA) or SPSS

Intervention groups

1

Description
Intervention group (Test): Celecoxib 200 mg capsules, produced by Daana Co. is the test product. In each period, 12 of 24 subjects will be given single oral dose of this product. In the second period, after washout, this group (test) will be in the reference group and will use brand drug (Celebrex, 200 mg).
Category
Treatment - Drugs

2

Description
Intervention group (Reference): Celecoxib 200 mg capsules (Celebrex), produced by Pfizer Company is the reference product. In each period, 12 of 24 subjects will be given single oral dose of this product. In the second period, after washout, this group (Reference) will be in the test group and will use domestic Celecoxib 200 mg capsules.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Drug Applied Research Center
Full name of responsible person
Dr Hamed Hamishehkar
Street address
Drug Applied Research Center, In front of Shahid Madani Hospital, Daneshghah Blvd, Tabriz, Iran
City
Tabriz
Province
East Azarbaijan
Postal code
5165665811
Phone
+98 41 3336 7914
Fax
+98 41 3336 7914
Email
hamishehkar.hamed@gmail.com
Web page address
https://darc.tbzmed.ac.ir/

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Daana pharmaceutical company
Full name of responsible person
Ahmad Kharazi
Street address
East Azerbaijan Province, Basmenj, Tehran - Tabriz Fwy
City
Tabriz
Province
East Azarbaijan
Postal code
5495151673
Phone
+98 41 3630 0586
Fax
+98 41 3630 0591
Email
name@domain.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Daana pharmaceutical company
Proportion provided by this source
100
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Industry

Person responsible for general inquiries

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Hamed Hamishehkar
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Pharmaceutics
Street address
Drug Applied Research Center, In front of Shahid Madani Hospital, Daneshghah Blvd, Tabriz, Iran
City
Tabriz
Province
East Azarbaijan
Postal code
5165665811

Phone
+98 41 3336 7914
Email
Hamishehkar.hamed@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Dr. Jaber Emami
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Pharmaceutics
Street address
Hezarjarib St., School of Pharmacy and Pharmaceutical Sciences , Isfahan, Iran
City
Isfahan
Province
Isfehan
Postal code
8174673461
Phone
+98 31 3792 7111
Fax
+98 31 3668 0011
Email
Emami@pharm.mui.ac.ir

Person responsible for updating data

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Fatima Molavi
Position
PhD student of Pharmaceutics
Latest degree
Medical doctor
Other areas of specialty/work
Pharmaceutics
Street address
Drug Applied Research Center, In front of Shahid Madani Hospital, Daneshghah Blvd, Tabriz, Iran
City
Tabriz
Province
East Azarbaijan
Postal code
5165665811
Phone
+98 41 3336 2700
Fax
Email
Molavif@tbzmed.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
No - There is not a plan to make this available
Informed Consent Form
No - There is not a plan to make this available
Clinical Study Report
No - There is not a plan to make this available
Analytic Code
No - There is not a plan to make this available
Data Dictionary
No - There is not a plan to make this available